Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting

BACKGROUND: A recently conducted matching-adjusted indirect comparison demonstrated that bosutinib improved progression-free survival, and delayed progression to advanced disease compared with dasatinib and nilotinib in patients with second line (2L) chronic-phase chronic myeloid leukemia (CP-CML)....

Descripción completa

Detalles Bibliográficos
Autores principales: Muresan, B., Mamolo, C., Cappelleri, J. C., Postma, M. J., Heeg, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8545733/
https://www.ncbi.nlm.nih.gov/pubmed/34250585
http://dx.doi.org/10.1007/s40258-021-00666-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8545733/
https://www.ncbi.nlm.nih.gov/pubmed/34250585
http://dx.doi.org/10.1007/s40258-021-00666-0

Ejemplares similares